Supplemental tables and figures
Supplemental Table 1 Details of 16 articles on VMS treatment
Author Publication
year Region Active
treatment
Sample size (placebo
group)
Mean Age (year)
Baseline VMS frequency
(per day)
VMS frequency reduction (per
day)
Baseline VMS severity
VMS severity reduction
Notelovitz et
al 2000 US HT 53 53.6±5.6 11.58 -5.54 NA NA
Archer et al 2003 US HT 73 51.0±5.6 11 -5.7 2.3 NA
Simon et al 2006 US HT 100 51.8±6.0 13.6 -7.2 NA NA
Buster et al a 2008 US HT 75 52±6.3 12.55 -5.32 2.54 NA
HT 76 52±7 12.13 -6.19 NA NA
HT 77 52.8±6.9 12.41 -4.76 NA -0.26
Speroff et al 2009 US SNRI 78 54.2±5.4 11 -5.5 2.5 -0.47
Archer et al 2009 US SNRI 153 53.4±5.0 10.9 -5.8 2.4 -0.33
Archer et al 2009 US SNRI 162 53.3±5.2 10.8 -6.3 2.4 -0.54 Stevenson et
al 2010 US HT 124 53.8±4.0 7.7 -4.9 NA NA
Bouchard et
al 2011 EU/South
Africa SNRI 150 54±5 9.6 -5.82 2.2 -0.61
Pinkerton et
al 2013 US SNRI 181 54±5 11.9 -5 2.4 -0.3
Archer et al 2014 US HT 183 53.4±6.5 10.57 -4.56 2.52 -0.39
Pinkerton et
al 2014 US Gabapentin 294 54.0±6.0 12 -6.5 2.54 -0.46
Archer et al 2016 US HT 96 53.9±5.3 11.8 -4.4 NA -0.3
Simon et al 2016 US Oxybutynin 75 54.1±4.6 10.84 -4.69 2.56 -0.3
Birkhaeuser
et al b 2019 US /EU TeCA 317 54.0±4.4 11.4 -4.88 2.44 -0.12
TeCA 314 53.5±4.9 12.1 -4.16 2.45 -0.08 Gaspard et
al 2020 US /EU HT 55 53.7±4.4 9.41 -6.28 2.5 -0.66
a. The study included three active treatment arms and another three placebo arms.
b. Two studies were included in this article.
HT: hormone therapy; NA: not applicable; SNRI: Serotonin and norepinephrine reuptake inhibitor; TeCA: Tetracyclic antidepressants; VMS: vasomotor symptom.
Supplemental Figure 1 Proportion of VMS frequency reduction at week 12 in each trial
Compared to baseline, the proportion of VMS frequency reduction ranged from 34.4% to 66.7%. Publication year, author, and sample size in placebo arm were presented for each trial. VMS: vasomotor symptom. VMS: vasomotor symptom.
Supplemental Figure 2 Absolute VMS frequency reduction at week 4 and week 12 from baseline
In trials with available frequency reduction result at week 4 and week 12, a further numerically improvement from week 4 to week 12 was observed in all the placebo arms. Publication year, author, and sample size in placebo arm were presented for each trial. VMS: vasomotor symptom. VMS: vasomotor symptom